Clinical Overview of Sorafenib in Breast Cancer

Alvaro Moreno-Aspitia


Future Oncol. 2010;6(5):655-663. 

In This Article

Sorafenib in Combination with other Agents

The combination of sorafenib with other targeted agents has also been explored. A Phase I trial combining sorafenib with bevacizumab has been reported. This dose-escalation trial in 39 patients with multiple tumor types indicated that, although efficacy might be increased with sorafenib and bevacizumab compared with single-agent therapy, the toxicity of the combination was also greater.[62] A total of 74% of patients in this trial required a decrease in sorafenib dose to 200 mg once daily (from an already reduced starting dose of 200 mg twice daily). Similarly, a Phase II study of the combination of bevacizumab and sorafenib in patients with MBC (Hoosier Oncology Group BRE06–109) was terminated early because of the significantly increased toxicity encountered.[102] Currently active protocols of sorafenib in breast cancer include its combination with chemotherapy agents, such as ixabepilone, vinorelbine, docetaxel, paclitaxel, gemcitabine and capecitabine, as well as endocrine agents such as fulvestrant, tamoxifen, anastrozole and letrozole.[56,102–112]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.